Drug Profile
Research programme: cancer vaccines - Cell Genesys/Juvaris
Alternative Names: Cancer vaccines - Cell Genesys/JuvarisLatest Information Update: 17 Oct 2006
Price :
$50
*
At a glance
- Originator Cell Genesys; Juvaris BioTherapeutics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Oct 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 20 Jul 2004 Preclinical trials in Cancer in USA (unspecified route)